Immunovant, Inc. (IMVT)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

30.47 on 9 Oct 2026

1 buy33 sales at will8 planned sales

Fiscal year 2026, ended 31 Mar 2026, as filed

Net income

$505.61M

Free cash flow

$407.32M

Return on equity

-59.3%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
7 Oct 2026	Stout Jay S Chief Technology Officer	Sold at will	$122.12K	1.9%
7 Oct 2026	Gloria Melanie Chief Operating Officer	Sold at will	$71.85K	1.0%
7 Oct 2026	Van Tuyl Christopher Chief Legal Officer	Sold at will	$42.54K	0.8%
2 Oct 2026	Venker Eric Chief Executive Officer	Sold at will	$119.59K	1.3%
23 Sep 2026	Van Tuyl Christopher Chief Legal Officer	Sold at will	$103.48K	1.6%
28 Aug 2026	Pande Atul Director	Sold on a plan	$64.91K	1.3%

35out of 100

Profitability 0

Financial strength 70

Growth n/a

Insiders 43

Strongest on financial strength (70), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$350.00M

1 buy, 1 buyer

Sold

$16.34M

41 sales

Planned sales

20%

under a 10b5-1 plan